Posted: October 17th, 2017
Teva Pharma S.L.U. & Ratiopharma Eshttp://eplaw.org/document/es-ap-barcelona-roche-c-teva-ratiopharma-judgment/paña S.A. v. F. Hoffmann La Roche AG, Provincial Court of Barcelona, Section 15, Spain, 22 May 2017, Appeal Docket Number: 739/2015.
In May 2017, Section 15 of the Barcelona Court of Appeals declared the nullity of patent ES 2.083.348 (ES 348), the Spanish part of patent EP 0.694.547 B1 (EP 547), owned by La Roche AG, due to lack of inventive step. Patent ES 348 protects the drug valganciclovir (monoester L-valinate of ganciclovir) and its salts, a process for preparing that compound and the use of the compound for the preparation of pharmaceutical compositions for the treatment of antivirals and related diseases. Valganciclovir is a prodrug of ganciclovir whose oral bioavailability is much higher than that of ganciclovir.
Headnote and summary: Luis Fernández-Novoa, HOYNG ROKH MONEGIER